RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

📢 ConnectM Technology Solutions (Nasdaq: CNTM) Institutional Ownership Surpasses 46% SRISID LLC has disclosed a 13.4% ownership in ConnectM through a Schedule 13G filing—signaling a strong vote of confidence in ConnectM Technology Solutions' growth trajectory. This addition brings total institutional ownership to 46.4%. 💡 Why This Matters for Investors: Growing Institutional Backing: Nearly half of ConnectM's shares are now held by institutional investors, enhancing credibility and visibility in capital markets. Strategic Momentum: The investment underscores belief in ConnectM's role in powering the energy transition through its Energy Intelligence Network platform. 🔗 https://lnkd.in/efrwMZGr #RedChip #RedChat #CNTM #AI #Electrification #EV #Investing #EnergyTransition #StockMarket

🎙️ Knightscope (Nasdaq: KSCP) CEO Interview: Inside the Vision to “Make America the Safest Country in the World” William Santana Li, Chairman & CEO of Knightscope, sits down for a wide-ranging interview discussing the company’s growth strategy, AI-powered security solutions, and long-term vision for transforming public safety. 💡 Why Investors Should Watch: - Federal Policy Momentum: Knightscope recently submitted formal recommendations to the The White House’s AI Action Plan, pushing for accelerated adoption of Autonomous Security Robots (ASRs) across government facilities. - Market Expansion: From military bases to commercial real estate, Knightscope is targeting multi-sector opportunities for scalable AI-driven security. - Leadership Insight: Hear directly from the CEO on how Knightscope is navigating regulation, innovation, and revenue growth in a rapidly evolving tech landscape. 🔗 https://lnkd.in/esZAReMm Public Safety Networks Law Enforcement Today Breaking Defense #AI #PublicSafety #NASDAQ #AutonomousSecurity #InvestorNews #FinancialNews

CyPath® Lung provided key diagnostic insight for an 85-year-old patient at extremely high risk with significant smoking history, COPD, and asbestos exposure. The test result of “Unlikely Lung Cancer” avoided a risky biopsy. After three months, all nodules had resolved. Explore the full case study to learn more about how CyPath® Lung supports informed clinical decision-making: https://bit.ly/4bNzZO6 #CyPathLung #lunghealth #lungnodule #HealthcareInnovation

📢 60 Degrees Pharmaceuticals, INC (Nasdaq: SXTP) Investor Webinar Scheduled for March 31 at 4:15 PM ET Investors are invited to join 60 Degrees Pharmaceuticals, INC for an upcoming webinar to learn more about the Company’s mission, clinical pipeline, and growth strategy in tackling infectious diseases with significant unmet need. 💡 Why This Matters for Investors: - Focused Expertise: 60P is advancing tafenoquine (ARAKODA®), already FDA-approved for malaria prevention, into new areas like chronic babesiosis, where no current treatments exist. - Clinical Pipeline Momentum: Recently received IRB approval for a Phase II study targeting chronic babesiosis, with enrollment expected in Q3 2025. - Market Potential: The addressable market for ARAKODA® in babesiosis alone exceeds 400,000 U.S. patients through 2035. 📅 Webinar Date: Monday, March 31 🕓 Time: 4:15 PM ET 🔗 https://lnkd.in/eJuqKR8M #RedChip #RedChat #60P #SXTP #PharmaStocks #MalariaPrevention #BiotechInvesting #HealthcareInnovation #FinancialNews

🚨 Can-Fite BioPharma (NYSE American: CANF) Launches Pivotal Phase 3 Psoriasis Trial 💊 Can Fite BioPharma (CANFY) has kicked off a Phase 3 clinical trial for Piclidenoson targeting moderate to severe plaque psoriasis. The study protocol is approved by both the FDA and EMA, with patient enrollment beginning in Europe and expanding to the U.S. and Canada. 📈 Why This Matters to Investors: - Regulatory Milestone: FDA and EMA protocol approval clears the path for potential NDA and MAA submissions. - Market Opportunity: Psoriasis market projected to reach $30B by 2030, with growing demand for safe, effective oral therapies. - Differentiated Profile: Piclidenoson’s twice-daily oral dose and strong safety data make it an attractive option for long-term treatment. 📄 https://lnkd.in/eSEqr9ZD Biotechnology Biotech Network #RedChip #RedChat #CanFiteBio #BiotechStocks #CANF #PharmaInvesting #ClinicalTrials

📢 Gorilla Technology Group (Nasdaq: GRRR) Reaffirms Confidence Amid Misinformation, Plans Insider Share Purchases Gorilla Technology Group is pushing back against recent market manipulation and confirms its leadership's strong belief in the company’s long-term value. 💡 Why This Matters to Investors: ✅ Insider Confidence: The Board and executive team, including CEO Jay Chandan, plan to purchase shares after the 2024 earnings release, signaling strong conviction in Gorilla's trajectory. ✅ Share Buyback Strategy: The company intends to resume its buyback program if undervaluation persists, reflecting confidence in Gorilla's fundamentals. ✅ Legal Clarity: The misinformation stems from individuals under federal indictment, and Gorilla Technology Group is actively addressing this through legal channels. 📄 https://lnkd.in/evhwJRmj #RedChip #RedChat #GorillaTech #SmartGrid #AI #EnergyInnovation #Thailand #TechInvesting #Infrastructure

🚨 Shareholder Approval Sets Stage for Strategic Transformation at Better Choice Company (NYSE American: BTTR) Better Choice Company (NYSE:BTTR) shareholders overwhelmingly approved the acquisition of SRx Health Solutions, marking a pivotal step toward becoming a broader health and wellness powerhouse. 💡 Why This Matters to Investors: ✅ Acquisition Greenlit: Signals confidence in future growth. ✅ Rebranding Ahead: Company name will change to SRX Health Solutions, Inc., with a new ticker—SRXH. ✅ Expanded Vision: Company expands beyond pet wellness, aligning with SRx’s healthcare platform and global opportunities. 📄 Read the Full Announcement: https://lnkd.in/eWdYVaBw Veterinary Practice News Veterinary Innovation Hub Biotechnology #HealthcareInnovation #Genomics #PetHealth #Investing #FinancialNews

📣 OS Therapies (NYSE American: OSTX) to Meet with Investors at Jones Trading Healthcare and Technology Innovation Conference OS Therapies CEO Paul Romness and CBO Gerald Commissiong will meet with institutional investors to discuss the Company’s progress and future growth plans the Jones Healthcare and Technology Innovation Conference on April 8–9, 2025, in Las Vegas. 💡 Why This Matters to Investors: ✅ Advancing Oncology Pipeline: Lead candidate OST-HER2 completed enrollment for a 41-patient Phase 2b osteosarcoma trial, with data expected in Q4 2024. ✅ Expanding Innovation: OS Therapies is developing a next-gen tunable ADC (tADC) platform, using proprietary linker tech for enhanced payload delivery. ✅ Strategic Visibility: The conference provides high-level exposure to capital markets, aligning with OS Therapies' biotech innovation focus. 📄 https://lnkd.in/eUCpd56p Biotechnology Antibody Drug Conjugates Journal for ImmunoTherapy of Cancer #RedChip #RedChat #OSTX #BiotechStocks #Immunotherapy #ADC #Investing #CancerResearch #StockMarket

🚀 PhoenixEV (Nasdaq: PEV) Secures RMB 1 Billion EV Expansion Deal in China! PhoenixEV's EdisonFuture International has partnered with Guorun Venture Capital to launch a RMB 1 billion (~$140M) M&A fund aimed at acquiring and developing EV manufacturing sites in China. This strategic move strengthens PhoenixEV's global EV production footprint, leveraging China’s supply chain advantages to scale cost-efficiently. 💡 Why This Matters for Investors: ✅ Global Expansion: Establishing a foothold in the world’s largest EV market. ✅ Strategic Growth: Access to low-cost capital and advanced manufacturing. ✅ Profitability Focus: Enhancing operational efficiencies for sustainable revenue growth. 📄 https://lnkd.in/etMX8JHK #PhoenixMotor #PEV #EVStocks #ElectricVehicles #SustainableInvesting